⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555233 | 0.81 | — | — | |
| SCHEMBL18706116 | 0.78 | MAPT (0.33) | — | |
| SCHEMBL19284176 | 0.76 | — | — | |
| SCHEMBL1189618 | 0.75 | JAK2 (0.33) | — | |
| SCHEMBL19300026 | 0.74 | — | — | |
| SCHEMBL28325161 | 0.72 | JAK2 (0.32) | — | |
| SCHEMBL2477631 | 0.69 | IDO1 (0.42) | — | |
| SCHEMBL19253470 | 0.69 | DRD3 (0.34) | — | |
| SCHEMBL24197645 | 0.67 | JAK2 (0.33) | — | |
| SCHEMBL13907209 | 0.67 | JAK2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387400-A1 | TYK2 INHIBITORS | BIOGEN MA INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4547674-A1 | TYK2 INHIBITORS | Biogen MA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119731186-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240409555-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-114206855-B | Cyanocyclobutyl compounds for Cbl-b inhibition and application thereof | 紐力克斯治疗公司 | 2024-11-26 | — | — | CN | disclosed |
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-12049471-B2 | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024006493-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3419978-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| CN-109071546-A | Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors | 辉瑞大药厂 | 2018-12-21 | — | — | CN | disclosed |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | PFIZER INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |